Question special

The supplementary appendix suggests that only ~ 50% of the patients were on a statin and less than < 50% were on antiplatelet in both arms. Arguments have been made that the good outcomes in ISCHEMIA and SCOT-HEART trials have been due to their good medical management. Although this study was executed before ischemia and scot-heart were published, I'm curious regarding the author's thoughts regarding whether the use of CCTA will lead to increase in statin/anti-platelet utilization.